Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers.

The Tohoku journal of experimental medicine - 1 Mar 2015

Maejima Ryuhei, Koike Tomoyuki, Nakagawa Kenichiro, Iijima Katsunori, Shimosegawa Tooru

Abstract excerpt

Gastroesophageal reflux disease (GERD) is a common disease, in which the reflux of gastric acid causes mucosal damage of the esophagus and/or troublesome symptoms. Esomeprazole, a proton pump inhibitor, has been used for treatment of GERD in Japan since 2011; namely, only little is known about its effect on gastric acid secretion in Japanese. We, therefore, assessed the relationship between dose and timing of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asian People
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Dose-Response Relationship, Drug

Share to Gastric Acid

Share to Helicobacter Infections

Share to Helicobacter pylori

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 25786769
DOI: 10.1620/tjem.235.249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers.PMID 25786769Read ↗

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.Semantic proximity Read ↗

Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.Semantic proximity Read ↗

Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.Semantic proximity Read ↗

[Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease].Semantic proximity Read ↗

Optimal management of severe symptomatic gastroesophageal reflux disease.Semantic proximity Read ↗

Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.Semantic proximity Read ↗

Gastroesophageal Reflux Disease.Semantic proximity Read ↗

Effect of a rabeprazole half-dose twice daily on acid inhibition in patients with different CYP2C19 alleles.Semantic proximity Read ↗

Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.Semantic proximity Read ↗

Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.Semantic proximity Read ↗

Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.Semantic proximity Read ↗

First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.